Processa Pharmaceuticals regains compliance with Nasdaq $1.00 minimum bid price; delisting matter closed

Processa Pharmaceuticals, Inc.

Received Nasdaq notification on January 6, 2026 confirming compliance with Listing Rule 5550(a)(2).
Company had previously been notified of bid price deficiency; now the deficiency is resolved.
Nasdaq Capital Market continued listing is no longer at risk from bid price requirement.
No other material changes; CEO George Ng signed the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.